Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | PRMT6 | Q96LA8 | 4/20 | 0.38 |
| ▸ | PRMT1 | Q99873 | 4/20 | 0.38 |
| ▸ | CARM1 | Q86X55 | 3/20 | 0.38 |
| ▸ | PRMT8 | Q9NR22 | 3/20 | 0.38 |
| ▸ | PRMT3 | O60678 | 1/20 | 0.38 |
| ▸ | NOS2 | P35228 | 6/20 | 0.38 |
| ▸ | NOS3 | P29474 | 5/20 | 0.38 |
| ▸ | NOS1 | P29475 | 5/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | NCF1 | P14598 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25122581 | 0.89 | KDM4E (0.37) | KDM4EALDH1A1PRMT6PRMT1CARM1 | |
| SCHEMBL12478430 | 0.83 | — | — | |
| SCHEMBL12478238 | 0.81 | PRMT1 (0.46) | KDM4EPRMT6PRMT1CARM1PRMT8 | |
| SCHEMBL8334637 | 0.79 | PRMT1 (0.44) | KDM4EPRMT6PRMT1CARM1PRMT8 | |
| SCHEMBL14980283 | 0.78 | KDM4E (0.41) | KDM4EALDH1A1NOS2NOS3NOS1 | |
| SCHEMBL2002550 | 0.78 | PRMT1 (0.42) | KDM4EPRMT6PRMT1CARM1PRMT8 | |
| SCHEMBL13162838 | 0.78 | KDM4E (0.41) | KDM4EALDH1A1NOS2NOS3NOS1 | |
| SCHEMBL21167214 | 0.78 | KDM4E (0.41) | KDM4EALDH1A1KMT2A | |
| SCHEMBL17059856 | 0.77 | DRD3 (0.38) | — | |
| SCHEMBL13209122 | 0.76 | KDM4E (0.41) | KDM4EALDH1A1NOS2NOS3NOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230218597-A1 | SUBSTITUTED PYRIDINES AND METHODS OF USE | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2023-07-13 | — | — | US | disclosed |
| US-20230218597-A1 | SUBSTITUTED PYRIDINES AND METHODS OF USE | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2023-07-13 | — | — | US | disclosed |
| US-11590116-B2 | Substituted pyridines and methods of use | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-02-28 | — | — | US | disclosed |
| WO-2021102468-A1 | SUBSTITUTED 1,5-NAPHTHYRIDINES OR QUINOLINES AS ALK5 INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2021-05-27 | — | — | WO | disclosed |
| US-20210154179-A1 | SUBSTITUTED PYRIDINES AND METHODS OF USE | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2021-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210154179-A1 | SUBSTITUTED PYRIDINES AND METHODS OF USE | ALK, ACVR1, ACVR2A | KDM4E 946/4885ALDH1A1 2453/4885PRMT6 1221/4885 |
| US-20230218597-A1 | SUBSTITUTED PYRIDINES AND METHODS OF USE | ALK, ACVR1, ACVR2A | KDM4E 946/4885ALDH1A1 2453/4885PRMT6 1221/4885 |
| US-11590116-B2 | Substituted pyridines and methods of use | ALK, ACVR1, ACVR2A | KDM4E 946/4885ALDH1A1 2453/4885PRMT6 1221/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.